The Board of Directors of the comoany at the meeting held on Wednesday, May 27, 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each ....
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medicamen Biotech's Board recommended a final dividend of Rs. 1 per equity share (10% on face value of Rs. 10) for FY 2025-26, pending shareholder approval at the AGM. The company reported standalone revenue of Rs. 17,885 Lacs (up 18% YoY) and standalone net profit of Rs. 941 Lacs (flat YoY). On consolidated basis, revenue grew 19% to Rs. 20,088 Lacs with net profit up 49% to Rs. 980 Lacs, boosted by subsidiaries Opal Pharmaceuticals and Medicamen Life Sciences. Cash position improved significantly to Rs. 3,108 Lacs from Rs. 358 Lacs last year. EPS stood at Rs. 6.94 (standalone) and Rs. 7.22 (consolidated).
The dividend is modest at 10% yield on face value but signals management confidence. Without current stock price data, yield impact cannot be assessed. The strong consolidated profit growth and improved cash position are positive indicators for shareholder returns.